抽动秽语综合征脑深部电刺激的疗效与安全性:国际公开数据库与登记研究
该前瞻性国际登记研究纳入10国31家机构的185例药物难治性抽动秽语综合征患者,评估脑深部电刺激(DBS)的疗效与安全性。术后1年耶鲁全球抽动严重程度量表总分及运动、发声抽动分均显著改善(P<.001),总体不良事件率为35.4%。
要点
- DBS术后1年YGTSS总分由75.01降至41.19,运动与发声抽动分均显著改善。
- 总体不良事件率35.4%,颅内出血1.3%、感染3.2%、电极取出0.6%。
- 最常见刺激相关不良反应为构音障碍6.3%与感觉异常8.2%。
核心结论
- DBS与抽动秽语综合征患者症状改善相关,但也伴随重要不良事件。
- 已提供关于抽动秽语综合征患者DBS结局的公开网站。
研究设计与样本
- 前瞻性国际DBS数据库与登记研究,纳入2012年1月1日至2016年12月31日在10国31家机构植入DBS的185例药物难治性抽动秽语综合征患者。
- 171例有可用数据,其中女性37例、男性134例,手术时平均(SD)年龄29.1(10.8)岁(范围13-58岁)。
主要发现
- YGTSS总分均值(SD)由基线75.01(18.36)改善至DBS植入后1年41.19(20.00)(P<.001)。
- 运动抽动分由基线21.00(3.72)改善至1年12.91(5.78)(P<.001),发声抽动分由16.82(6.56)改善至9.63(6.99)(P<.001)。
- 151例中97例(64.2%)存在强迫症状,148例中32例(21.6%)有自伤行为史。
- 总体不良事件率35.4%(158例中56例),颅内出血2例(1.3%),感染4例共5次事件(3.2%),电极取出1例(0.6%)。
- 刺激诱发不良事件最常见为构音障碍10例(6.3%)和感觉异常13例(8.2%)。
关键数值与推荐
- 刺激靶点:丘脑中央中核区93/163(57.1%)、苍白球内侧部前部41/163(25.2%)、苍白球内侧部后部25/163(15.3%)、内囊前肢4/163(2.5%)。
临床怎么用
- 对药物难治性抽动秽语综合征患者,DBS可作为改善抽动症状的候选治疗,但需充分告知不良事件风险。
- 术后随访应关注颅内出血、感染及构音障碍、感觉异常等刺激相关不良反应。
局限性
- 原文摘要未报告对照设计、盲法及长期随访结果等局限信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Collective evidence has strongly suggested that deep brain stimulation (DBS) is a promising therapy for Tourette syndrome. OBJECTIVE: To assess the efficacy and safety of DBS in a multinational cohort of patients with Tourette syndrome. DESIGN, SETTING, AND PARTICIPANTS: The prospective International Deep Brain Stimulation Database and Registry included 185 patients with medically refractory Tourette syndrome who underwent DBS implantation from January 1, 2012, to December 31, 2016, at 31 institutions in 10 countries worldwide. EXPOSURES: Patients with medically refractory symptoms received DBS implantation in the centromedian thalamic region (93 of 163 [57.1%]), the anterior globus pallidus internus (41 of 163 [25.2%]), the posterior globus pallidus internus (25 of 163 [15.3%]), and the anterior limb of the internal capsule (4 of 163 [2.5%]). MAIN OUTCOMES AND MEASURES: Scores on the Yale Global Tic Severity Scale and adverse events. RESULTS: The International Deep Brain Stimulation Database and Registry enrolled 185 patients (of 171 with available data, 37 females and 134 males; mean [SD] age at surgery, 29.1 [10.8] years [range, 13-58 years]). Symptoms of obsessive-compulsive disorder were present in 97 of 151 patients (64.2%) and 32 of 148 (21.6%) had a history of self-injurious behavior. The mean (SD) total Yale Global Tic Severity Scale score improved from 75.01 (18.36) at baseline to 41.19 (20.00) at 1 year after DBS implantation (P < .001). The mean (SD) motor tic subscore improved from 21.00 (3.72) at baseline to 12.91 (5.78) after 1 year (P < .001), and the mean (SD) phonic tic subscore improved from 16.82 (6.56) at baseline to 9.63 (6.99) at 1 year (P < .001). The overall adverse event rate was 35.4% (56 of 158 patients), with intracranial hemorrhage occurring in 2 patients (1.3%), infection in 4 patients with 5 events (3.2%), and lead explantation in 1 patient (0.6%). The most common stimulation-induced adverse effects were dysarthria (10 [6.3%]) and paresthesia (13 [8.2%]). CONCLUSIONS AND RELEVANCE: Deep brain stimulation was associated with symptomatic improvement in patients with Tourette syndrome but also with important adverse events. A publicly available website on outcomes of DBS in patients with Tourette syndrome has been provided.
引用
- Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, et al. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. JAMA Neurol. 2018. PMID: 29340590. doi:10.1001/jamaneurol.2017.4317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。